Myeloproliferative neoplasms are chronic myeloid cancers divided in Philadelphia positive and negative. The JAK2 V617F is the most common mutation in Philadelphia nega- 
| INTRODUC TI ON
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by an uncontrolled proliferation of one or more elements of the myeloid lineage.
1 In addition to chronic myeloid leucemia (CML), characterized by the presence of the Philadelphia chromosome, the Philadelphia negative MPNs are essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The JAK2 V617F is the most frequent mutation in patients affected by PV, ET and PMF. JAK2 gene encodes for a non-receptor tyrosine kinase crucial for signal transduction downstream of the erythropoietin, thrombopoetin and related receptors that control erythrocyte and megakaryocyte expansion. and it is regulated by AKT. In normal cells, mTORC1 is essential for erythroid and megakaryocytic differentiation through the activation of downstream effectors including 4eBP1 and p70s6K. 6 This pathway has been found deregulated particularly in megakaryocytes of MPNs patients. 7 The deregulation of JAK/STAT and mTOR pathways induces an inflammatory state with aberrant cytokine expression. 8 Given the heterogeneous clinical needs of MPNs patients, determination of a standard therapeutic protocol is often difficult. Moreover, targeted therapy with JAK inhibitors revealed to have some limits in terms of efficacy, 9 therefore it is necessary to find additional approaches to improve the results so far obtained.
Curcumin is the active phytochemical component isolated from the rhizome of the Curcuma longa plant. Curcumin is a highly pleiotropic molecule with multiple pharmacological effects, such as antiinflammatory, anti-microbial, anti-oxidative and anti-proliferative activities. 10, 11 Extensive preclinical trials have indicated curcumin therapeutic potential against a wide range of human diseases.
12
Previous studies showed that curcumin can suppress JAK2/STAT signalling pathways in different type of cancer and injuries. 13, 14 Chen et al demonstrated that curcumin increased the transcript levels of SOCS-3, an important negative regulator of JAK2, and significantly inhibited the clonogenic activity of hematopoietic progenitors from MPNs patients. 15 Furthermore, curcumin was able to dissociate Raptor from mTOR, by inhibiting mTORC1 signalling and the phosphorylation of its downstream effectors in different cell lines. 16 In this study, we investigated the effect of curcumin on JAK2
V617F cell line and in primary cells from MPNs patients. Our results suggest that curcumin inhibits proliferation and activates cell death program by modulating JAK2/STAT and mTORC1 pathways.
| MATERIAL S AND ME THODS

| Cells culture conditions
HEL cell line was purchased from American Type Culture Collection (ATCC, Manassas, USA). HEL cells were grown in RPMI 1640 medium supplemented with 200 nmol/L Glutamine (EuroClone), 10% inactivated foetal bovine serum (FBS, Sigma-Aldrich) and 0.1% penicillin/streptomycin and maintained at 37°C with 5% CO 2 . 
| Patients cohort
| Apoptosis and viability assays
Apoptosis was evaluated using APC Annexin V (BioLegend), accord- Quantification was performed using Image Lab program (Bio-Rad). Cruz Biotechnology). mTOR antibody (Table 1) for co-immunoprecipitation was added to the lysate (1 mg/mL) and incubated ON at 4°C. Protein A/G (20 μL) were added to the antibody and lysate mixture and incubated 1 hour at 4°C in a rotator. The mock control (beads and whole cell lysates without adding antibody) was used to exclude the false interaction of lysate proteins with the beads.
| Protein extraction and immunoblotting
| Co-immunoprecipitation
Immunoprecipitates and mock controls were washed once with CHAPS buffer lacking NaCl and three times with CHAPS buffer containing 150 mmol/L NaCl. Samples were eluted in 5× Laemmli buffer at 95°C for 10 minutes and resolved on 6% SDS-PAGE as described above. mTOR-Raptor complex was evaluated using mTOR and Raptor antibodies (Table 1) as previously described.
| RNA extraction and qRT-PCR analysis
Total RNA was extracted using TRIzol Reagent (Ambion, Thermo 
| Statistical analysis
Statistical analyses were performed using the two-tailed MannWhitney U test and paired t test. All the analysis with confidence level major of 95% are indicated like significant and marked as followed: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
| RE SULTS
| Curcumin induces apoptosis and inhibits viability in HEL cells
To explore the effects of curcumin on cell death and viability, HEL cells were treated with various concentrations of curcumin (0-30 µmol/L) for 24/48 hours, proliferation and apoptosis were evaluated by FACS and immunoblotting. The viability of the HEL cells exposed to curcumin was significantly lower compared to control cells even at low 
| Curcumin modulates mTORC1 signalling by the inhibition of PDK and AKT in HEL cells line
To investigate how curcumin affects mTORC1 pathway, HEL cells ) . B, Effect of curcumin on apoptosis (n = 5). C, Caspase-3 Cleaved expression was evaluated by SDS-PAGE. The GAPDH level was used as loading control. The relative intensity of each band is shown under the blot as fold change (FC) compared to untreated control, to which a value of 1 unit was assigned. Statistical analyses were performed using the two-tailed Mann-Whitney U test, comparing conditions two by two respect to not treated condition. All the analysis with confidence level major of 95% are indicated like significant and marked as followed: *P ≤ 0.05; **P ≤ 0.01.
for 24 hours and analysed by immunoblotting. Our results indicated that curcumin affects the principal modulator of mTORC1: AKT.
Phosphorylation of AKT in Thr308 was reduced in dose-dependent manner and its principal activator PDK was inhibited by low dose curcumin and it appeared unphosphorylated at the maximum concentration utilized (Figure 3 ). The consequence was the reduction of the complex between mTOR and Raptor, as observed in Figure 3 , especially at the highest drug concentration. Furthermore, by analysing the signal cascade, we observed the deregulation of the principal downstream effectors of mTORC1. In particular, we showed the dephosphorylation of p70s6K, which is usually activated by phosphorylation, and the increase of unphosphorylated form of 4eBP1, usually inhibited through mTORC1 phosphorylation.
| Curcumin induces apoptosis and reduces PIM family members and CD177 expression in JAK2 mutated MPNs patients
Due to the promising results in vitro, we tried to evaluate the effect of curcumin also in patient specimens. For these purposes, leucocytes from JAK2 mutated patients were treated with curcumin at the high- . Statistical analyses were performed using the twotailed Mann-Whitney U test, comparing conditions two by two respect to not treated condition. All the analysis with confidence level major of 95% are indicated like significant and marked as followed: *P ≤ 0.05; **P ≤ 0.01. expression of PIM family members and CD177 were evaluated by qRT-PCR. The results were in accordance with in vitro analysis and showed that PIM1, PIM2, PIM3 and CD177 mRNA expression was significantly down-regulated in cells treated with curcumin compared to not treated samples (PIM1 P = 0.0014; PIM2 P = 0.0073; PIM3 P = 0.011; CD177 P < 0.0001) ( Figure 4A ). Interestingly, except for PIM2 (P = 0.025) ( Figure 4A ), the mRNA expression of PIM family members and CD177
after treated return to the levels of healthy subjects (PIM1 P = 0.1;
PIM3 P = 0.07 and CD177 P = 0.58). Furthermore, the expression of cleaved caspase-3, evaluated by SDS-PAGE, was significantly up-regulated in patients' cells treated with curcumin (P < 0.001), while it has not changed in cells from healthy donors ( Figure 4B ). These results suggest that curcumin treatment affects JAK/STAT pathway and induces apoptosis in cells from JAK2 V617F mutated patients.
| D ISCUSS I ON
The As a consequence, we observed a strong inhibition of mTORC1 downstream effectors 4eBP1 and p70s6K phosphorylation, both involved in cell growth and proliferation. 16 This data are in accordance with the hypothesis that mTORC1 is a JAK2 downstream pathway and it is involved in MPNs pathogenesis. 25 Due to the promising data obtained in cell line, we tried to evaluate the effect of curcumin also in patient samples. Our preliminary data showed that the in vitro curcumin treatment of cells from MPNs patients significantly reduced the expression of PIM family members, bringing back their mRNA expressions to comparable levels with healthy subjects ones. The curcumin effect was strengthened by the observation that CD177, an antigen over expressed in neutrophils of the majority of MPNs patients, was down-regulated by curcumin. 26 Ishida et al demonstrated that HEL cells are only partially dependent on JAK2 V617F for survival and this may explain the very limited effect of ruxolitinib and its inefficiency to eradicate JAK2-mutated clone in MPNs patients. 27 Interestingly, in this study, we observed that curcumin affects both proliferation and survival of HEL cells, suggesting that its role in MPNs could be more effective in blocking neoplastic cells respect to the common JAK2 inhibitors, such as ruxolitinib. In vitro studies support this hypothesis by indicating that co-treatment of mTOR and JAK2 inhibitors resulted in synergistic activity against JAK2 V617F-mutated cells, 5 although mTORC1 inhibitors can cause numerous side effects that could prevent their use. 28 In contrast, curcumin turned out to be safe and non-toxic in many different trials, 29, 30 so its use for MPNs treatment could represent an excellent alternative to common mTORC1 inhibitors. Although the curcumin employment for MPNs treatment needs to be further investigated, our preclinical data encourage its use for the future therapies. . Statistical analyses were performed using paired t test to compare treated and not treated MPNs patients' cells and the two-tailed Mann-Whitney U test to compare treated patients with healthy donors' cells. All the analysis with confidence level major of 95% are indicated like significant and marked as followed: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. B, Caspase-3 Cleaved expression was evaluated by SDS-PAGE. The GAPDH level was used to normalize data. Representative Western blots of three patients and three healthy controls were shown
In conclusion, this study showed that curcumin exerts an antitumor effect on human JAK2-mutated cells by inducing apoptosis and inhibition of proliferation, through the regulation of both JAK2/STAT and mTORC1 pathways. These findings suggest that curcumin seems to be a promising nutraceutical compound that should be further evaluated in different pharmaceutical formulation for the treatment of MPNs.
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